- Home
- Publications
- Publication Search
- Publication Details
Title
Integrin Inhibitors in Prostate Cancer
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 2, Pages 44
Publisher
MDPI AG
Online
2018-02-07
DOI
10.3390/cancers10020044
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of Laminin Binding Integrin Internalization in Prostate Cancer Cells
- (2017) Lipsa Das et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression
- (2017) Yuan Jiang et al. MOLECULAR CANCER RESEARCH
- Metformin inhibits SUV39H1-mediated migration of prostate cancer cells
- (2017) T Yu et al. Oncogenesis
- Selection and Characterization of an α6β4 Integrin blocking DNA Aptamer
- (2016) Katharina Berg et al. Molecular Therapy-Nucleic Acids
- Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly
- (2015) Edward R. Horton et al. NATURE CELL BIOLOGY
- Targeting of αv-Integrins in Stem/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in Human Prostate Cancer
- (2015) Geertje van der Horst et al. NEOPLASIA
- Aptamers as Drug Delivery Vehicles
- (2014) Sven Kruspe et al. ChemMedChem
- A d-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization
- (2014) Donna M. Veine et al. CLINICAL & EXPERIMENTAL METASTASIS
- A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin
- (2014) Xiuqi Kong et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane Antigen
- (2014) Justin P Dassie et al. MOLECULAR THERAPY
- A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer
- (2014) Vittorio de Franciscis MOLECULAR THERAPY
- The integrin adhesome: from genes and proteins to human disease
- (2014) Sabina E. Winograd-Katz et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- α5β1 Integrin Ligand PHSRN Induces Invasion and α5 mRNA in Endothelial Cells to Stimulate Angiogenesis
- (2014) Zhao-Zhu Zeng et al. Translational Oncology
- Chlorin e6 Conjugated Interleukin-6 Receptor Aptamers Selectively Kill Target Cells Upon Irradiation
- (2014) Sven Kruspe et al. Molecular Therapy-Nucleic Acids
- Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy
- (2014) Jiehua Zhou et al. Molecular Therapy-Nucleic Acids
- D-pinitol Inhibits Prostate Cancer Metastasis through Inhibition of αVβ3 Integrin by Modulating FAK, c-Src and NF-κB Pathways
- (2013) Tien-Huang Lin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis
- (2013) Belal AL-Husein et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeting Constitutively Activated β 1 Integrins Inhibits Prostate Cancer Metastasis
- (2013) Yu-Chen Lee et al. MOLECULAR CANCER RESEARCH
- IGF-IR Promotes Prostate Cancer Growth by Stabilizing α5β1 Integrin Protein Levels
- (2013) Aejaz Sayeed et al. PLoS One
- Contortrostatin, a homodimeric disintegrin isolated from snake venom inhibits herpes simplex virus entry and cell fusion
- (2012) Stephen Hubbard et al. ANTIVIRAL THERAPY
- Statin Use and Reduced Cancer-Related Mortality
- (2012) Sune F. Nielsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-Angiogenic Peptides for Cancer Therapeutics
- (2011) Elena V. Rosca et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Statins and prostate cancer: Molecular and clinical aspects
- (2011) Georgios Papadopoulos et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases
- (2010) Mark A ROSENTHAL et al. Asia-Pacific Journal of Clinical Oncology
- Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium
- (2010) Deborah A. Bradley et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
- (2010) Ajjai Alva et al. INVESTIGATIONAL NEW DRUGS
- Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression
- (2010) S. T. Kochuparambil et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo
- (2010) Edwin Lin et al. PROSTATE
- Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells
- (2008) A. Hoque et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Antibody-Mediated Blockade of Integrin v 6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor- Regulated Mechanism
- (2008) L. A. Koopman Van Aarsen et al. CANCER RESEARCH
- Integrins in prostate cancer progression
- (2008) H. L. Goel et al. ENDOCRINE-RELATED CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started